|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0763 EUR | +2.83% |
|
+4.66% | +17.02% |
| Mar. 09 | TME Pharma Secures 12-month Loan Extension | MT |
| Jan. 05 | TME Pharma N.V. Provides Update on Its Activities | CI |
Company Valuation: TME Pharma N.V.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 7.587 | 24.37 | 17.44 | 1.653 | 1.22 | 7.059 |
| Change | - | 221.14% | -28.42% | -90.52% | -26.24% | 478.85% |
| Enterprise Value (EV) 1 | 6.331 | 14.17 | 10.42 | 1.105 | 0.1405 | 3.819 |
| Change | - | 123.79% | -26.43% | -89.4% | -87.29% | 2,618.09% |
| P/E ratio | -7.28x | -1.75x | -1.07x | -0.09x | -0.17x | -0.47x |
| PBR | -4.12x | 3.43x | 3.86x | -1.65x | -13.5x | 4.37x |
| PEG | - | -0x | 0x | 0x | 0x | 0x |
| Capitalization / Revenue | 49.3x | 696x | 528x | - | - | - |
| EV / Revenue | 41.1x | 405x | 316x | - | - | - |
| EV / EBITDA | -1.57x | -2.44x | -0.78x | -0.09x | -0.03x | -0.73x |
| EV / EBIT | -1.56x | -2.43x | -0.77x | -0.09x | -0.02x | -0.73x |
| EV / FCF | -1.06x | -3.46x | -1.42x | -0.15x | -0.04x | -1.4x |
| FCF Yield | -94.7% | -28.9% | -70.6% | -665% | -2,543% | -71.5% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -8 | -32.16 | -21.9 | -12.86 | -1.342 | -0.159 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 0.154 | 0.035 | 0.033 | - | - | - |
| EBITDA 1 | -4.044 | -5.807 | -13.44 | -11.99 | -5.593 | -5.241 |
| EBIT 1 | -4.064 | -5.824 | -13.46 | -12.01 | -5.624 | -5.258 |
| Net income 1 | -0.861 | -10.4 | -14.45 | -15.13 | -6.736 | -5.722 |
| Net Debt 1 | -1.256 | -10.2 | -7.016 | -0.548 | -1.079 | -3.24 |
| Reference price 2 | 58.2000 | 56.2000 | 23.4000 | 1.2158 | 0.2300 | 0.0750 |
| Nbr of stocks (in thousands) | 130 | 434 | 745 | 1,360 | 5,302 | 94,122 |
| Announcement Date | 4/22/20 | 4/28/21 | 4/22/22 | 4/24/23 | 4/25/24 | 4/25/25 |
1EUR in Million2EUR
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 8.36M | |
| 34.13x | 5.07x | 16.98x | 0.99% | 44.92B | |
| 55.12x | 4.79x | 32.28x | -.--% | 33.88B | |
| 54.71x | 11.2x | 31.35x | 0.35% | 30.76B | |
| 20.73x | 2.42x | 10.44x | -.--% | 28.69B | |
| -12.91x | 336.23x | -10.94x | -.--% | 19.59B | |
| 45.09x | 8.62x | 27.06x | -.--% | 14.76B | |
| 27.3x | 4.36x | 19.81x | -.--% | 13.25B | |
| 20.82x | 1.92x | 8.38x | 1.18% | 13.06B | |
| Average | 30.62x | 46.83x | 16.92x | 0.32% | 22.1B | |
| Weighted average by Cap. | 33.81x | 38.21x | 18.49x | 0.35% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- ALTME Stock
- Valuation TME Pharma N.V.
Select your edition
All financial news and data tailored to specific country editions
